All In Biotech

NDA 020989 · Cosette

Evoxac

Cevimeline Hydrochloride · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Nov 1, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jan 11, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

1 Phase 3, 0 recruiting

FAERS reports

2,791

1,462 serious, 109 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 9, 2026.

EVOXAC is indicated for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. EVOXAC is a cholinergic agonist indicated for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. ( 1 )

Mechanism: Cevimeline is a cholinergic agonist which binds to muscarinic receptors in various exocrine glands.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 11, 2000 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
1 products under this application
  • EVOXAC · CEVIMELINE HYDROCHLORIDE 30MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Cevimeline" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective218
  • headache184
  • nausea171
  • diarrhoea169
  • fatigue162
  • dyspnoea146
  • pain133
  • arthralgia124
  • off label use111
  • fall109
  • malaise100
  • dizziness97

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200430
200529
200631
200739
200841
200954
201068
201174
201297
2013123
2014105
2015174
2016251
2017164
2018177
2019196
2020151
2021125
2022152
2023133
2024196
2025181
2026200

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Evoxac (Cevimeline HCl)

2024 spending

$1.0M

Beneficiaries

183

797 claims

Per beneficiary

$5,539

$7.69 per unit

View as table
YearSpending
2020$0
2021$0
2022$291,979
2023$1,166,165
2024$1,013,650

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 27 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.